SHAREHOLDER ALERT: Weiss Law Investigates Columbia Care Inc.

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Columbia Care Inc. ("Columbia Care" or the "Company") (OTCQX: CCHWF) in connection with its proposed merger with Cresco Labs ("Cresco") (OTCQX: CRLBF). Under the terms of the merger agreement, the Company's shareholders will receive 0.5579 shares of Cresco for each share of Columbia Care common stock owned, representing an implied per-share merger consideration of approximately $3.25 based upon Cresco's March 24, 2022 closing price of $5.82 . Upon completion of the transaction, Cresco shareholders will own approximately 65% and Columbia Care shareholders will own only 35% of the combined company.

If you own Columbia Care shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/cchwf
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7 th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Weiss Law is investigating whether: (i) Columbia Care's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Columbia Care's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-columbia-care-inc-301511011.html

SOURCE WeissLaw LLP

News Provided by PR Newswire via QuoteMedia

CL:CNX,CRLBF
The Conversation (0)
Cannabis plant in focus, blurred US flag background.

Analysts React: Trump Signs Executive Order to Reschedule Cannabis

The long-debated issue of US cannabis rescheduling is finally back in the spotlight. On Thursday (December 18), President Donald Trump signed an executive order to expedite the process of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Market watchers are now... Keep Reading...
Close-up of green cannabis leaves in natural light.

Trump Weighs Executive Order to Loosen Federal Cannabis Restrictions

US President Donald Trump is reportedly weighing a major shift in federal drug policy that would relax decades-old restrictions on cannabis, potentially injecting new life into the industry. Six people familiar with the discussions told the Washington Post that Trump is preparing an executive... Keep Reading...
Gavel on a surface with scattered cannabis leaves, symbolizing legal issues around marijuana.

Hemp THC Recriminalization: A Blow to a Blooming Industry

A spending bill to reopen the US government after a 43 day shutdown includes provisions that will recriminalize most hemp-derived THC products. This change, slated to become effective one year after enactment, in late 2026, marks a significant policy reversal from the 2018 Farm Bill, which... Keep Reading...
Cannabis buds on a wooden surface with Australian banknotes nearby.

Australia's Cannabis Import Quota Slashed Amid Surging Local Production

Australia’s Office of Drug Control (ODC) said the country’s 2025 cannabis import quota has been reduced by the International Narcotics Control Board from 101 tonnes to 88 tonnes, Business of Cannabis reported.Over-projected demand and idle permits that limited operational flexibility were cited... Keep Reading...
Gavel resting on cannabis leaves.

Cannabis Crossroads: Record US Demand Meets Federal Gridlock

The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2025

After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...

Interactive Chart

Latest Press Releases

Related News